Loading
PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
Latest quote
¥333
−¥5.00 · -1.48%
Regular session · JST · Market data may be delayed.
PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
Day range
Current ¥333
52-week range
Current ¥333
Regular session · JST · Market data may be delayed.
PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
Day range
Current ¥333
52-week range
Current ¥333
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.57B JPY | 1.54B JPY | 1.72B JPY | 2.12B JPY | 1.32B JPY |
| Cost of goods sold | 376.45M JPY | 433.28M JPY | 520.26M JPY | 567.6M JPY | 597.03M JPY |
| Gross profit | 1.19B JPY | 1.11B JPY | 1.2B JPY | 1.56B JPY | 727.79M JPY |
| Research and development | 191.38M JPY | 273.75M JPY | 206.86M JPY | 205.48M JPY | 219.77M JPY |
| Selling, general, and administrative | 914.93M JPY | 969.53M JPY | 975M JPY | 836M JPY | 665M JPY |
| Operating expenses | 1.11B JPY | 1.24B JPY | 1.18B JPY | 1.05B JPY | 895.41M JPY |
| Interest income | 9.41M JPY | 8.33M JPY | 5.96M JPY | 2.23M JPY | 203K JPY |
| Interest expense | 4.8M JPY | 5.25M JPY | 2.93M JPY | 3.07M JPY | 952K JPY |
| Depreciation and amortization | 33.75M JPY | 28.2M JPY | 25.23M JPY | 23.7M JPY | 86.24M JPY |
| Operating income | 82.77M JPY | −135.17M JPY | 11.06M JPY | 508.45M JPY | −167.62M JPY |
| Net income | 125.23M JPY | −445.65M JPY | 26.38M JPY | 493.33M JPY | −387.97M JPY |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
